send mail to email@example.com mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
Please verify your mobile number
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Refer & Earn
My Abhipedia Earning
Kindly Login to view your earning
The Drug Controller General of India (DCGI) gave approval to another indigenous COVID-19 vaccine candidate called CORBEVAX for two clinical trials.
This vaccine is also called as BioE COVID-19 vaccine. This COVID-19 vaccine candidate has been developed by Indian biopharmaceutical firm Biological E. Limited (BioE) in collaboration with the Baylor College of Medicine, Houston in United States and American company Dynavax Technologies (DVAX). Vaccine is a protein subunit vaccine. Ministry of Health and Family Welfare has already ordered 300 million doses of Corbevax in June 2021.
U.S. International Development Finance Corporation (DFC) announced in April 2021 to fund the expansion of BioE’s manufacturing capabilities in order to produce at least 1 billion doses by end of 2022.
Phase I clinical trial was carried in 360 participants in order to evaluate the safety and immunogenicity of the vaccine candidate. Its phase II trial was concluded in April 2021. Permission to conduct phase III clinical trials was given in April 2021.
By: Brijesh Kumar ProfileResourcesReport error
Access to prime resources